Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease
Public ClinicalTrials.gov record NCT03625622. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A double-blinded, randomized, placebo-controlled study will be performed to evaluate the efficacy and safety of treating AR1001 in patients with mild to moderate Alzheimer's disease for 26 weeks.
Study identification
- NCT ID
- NCT03625622
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 210 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 55 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2019
- Primary completion
- Dec 21, 2020
- Completion
- Jun 27, 2021
- Last update posted
- Jul 20, 2021
2019 – 2021
United States locations
- U.S. sites
- 21
- U.S. states
- 11
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Advanced Clinical Research, Inc. | Banning | California | 92220 | — |
| Northern California Research | Sacramento | California | 95821 | — |
| Syrentis Clinical Research | Santa Ana | California | 92705 | — |
| Meridien Research | Lakeland | Florida | 33805 | — |
| Meridien - Maitland | Maitland | Florida | 32751 | — |
| The Neurology Research Group | Miami | Florida | 33176 | — |
| Accelerated Enrollment Solutions (AES) | Orlando | Florida | 32806 | — |
| IMIC, Inc | Palmetto Bay | Florida | 33157 | — |
| Meridien Research - Spring Hill | Spring Hill | Florida | 34609 | — |
| Meridien Research - St Petersburg | St. Petersburg | Florida | 33709 | — |
| Meridien Research - Tampa | Tampa | Florida | 33634 | — |
| NeuroStudies, LLC | Decatur | Georgia | 30033 | — |
| Advanced Clinical Research | Meridian | Idaho | 83642 | — |
| Wake Research - CRCNV | Las Vegas | Nevada | 89106 | — |
| Rapid Medical Research | Beachwood | Ohio | 44122 | — |
| Lynn Health Science Institute | Oklahoma City | Oklahoma | 73112 | — |
| Palmetto Clinical Research | Summerville | South Carolina | 29485 | — |
| Advanced Clinical Research - Cedar Park | Cedar Park | Texas | 78613 | — |
| FMC Science | Lampasas | Texas | 76550 | — |
| Advanced Clinical Research, Inc. | West Jordan | Utah | 84088 | — |
| Kingfisher Cooperative, LLC | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03625622, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 20, 2021 · Synced Sep 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03625622 live on ClinicalTrials.gov.